Xintela AB (publ) (STO:XINT)
Sweden · Delayed Price · Currency is SEK 0.1855
+0.0045 (2.49%)
Aug 13, 2026, 5:29 PM CET
Xintela AB Market Cap
Xintela AB has a market cap or net worth of 155.89 million as of August 13, 2026. Its market cap has decreased by -36.89% in one year.
Market Cap
155.89M
Enterprise Value
167.88M
Revenue
2.59M
Ranking
n/a
PE Ratio
n/a
Stock Price
0.19
ChartMarket Cap Chart
Since March 22, 2016, Xintela AB's market cap has increased from 103.68M to 155.89M, an increase of 50.36%. That is a compound annual growth rate of 4.00%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 12, 2026 | 155.89M | -21.54% |
| Dec 30, 2025 | 198.68M | 5.85% |
| Dec 30, 2024 | 187.69M | 26.87% |
| Dec 29, 2023 | 147.94M | -1.74% |
| Dec 30, 2022 | 150.56M | -26.24% |
| Dec 30, 2021 | 204.12M | 2.23% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xbrane Biopharma AB | 197.40M |
| Elicera Therapeutics AB | 196.87M |
| Alzinova AB | 186.83M |
| Initiator Pharma | 177.98M |
| Abera Bioscience AB | 166.45M |
| Diamyd Medical AB | 158.70M |
| Biovica International AB | 153.55M |
| Nanologica AB | 148.60M |